Immutep Ltd ADR (IMMP) - Total Assets
Based on the latest financial reports, Immutep Ltd ADR (IMMP) holds total assets worth $147.20 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Immutep Ltd ADR balance sheet independence to measure how much of total assets are equity-financed.
Immutep Ltd ADR - Total Assets Trend (2008–2025)
This chart illustrates how Immutep Ltd ADR's total assets have evolved over time, based on quarterly financial data. Check IMMP cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Immutep Ltd ADR - Asset Composition Analysis
Current Asset Composition (June 2025)
Immutep Ltd ADR's total assets of $147.20 Million consist of 95.0% current assets and 5.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.9% |
| Accounts Receivable | $7.46K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.09 Million | 4.5% |
| Goodwill | $109.96K | 0.1% |
Asset Composition Trend (2008–2025)
This chart illustrates how Immutep Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Immutep Ltd ADR.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immutep Ltd ADR's current assets represent 95.0% of total assets in 2025, an increase from 41.9% in 2008.
- Cash Position: Cash and equivalents constituted 42.9% of total assets in 2025, up from 39.3% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 20.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 4.5% of total assets.
Immutep Ltd ADR Competitors by Total Assets
Key competitors of Immutep Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Immutep Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.97 | 18.86 | 11.94 |
| Quick Ratio | 2.97 | 18.86 | 11.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $92.78 Million | $164.55 Million | $57.05 Million |
Immutep Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Immutep Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | -22.1% |
| Total Assets | $156.98 Million |
| Market Capitalization | $84.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Immutep Ltd ADR's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Immutep Ltd ADR's assets decreased by 22.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immutep Ltd ADR (2008–2025)
The table below shows the annual total assets of Immutep Ltd ADR from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $156.98 Million | -22.12% |
| 2024-06-30 | $201.58 Million | +36.71% |
| 2023-06-30 | $147.45 Million | +44.32% |
| 2022-06-30 | $102.17 Million | +24.55% |
| 2021-06-30 | $82.03 Million | +76.04% |
| 2020-06-30 | $46.60 Million | +14.94% |
| 2019-06-30 | $40.54 Million | -13.74% |
| 2018-06-30 | $47.00 Million | +34.42% |
| 2017-06-30 | $34.96 Million | -17.84% |
| 2016-06-30 | $42.55 Million | +37.34% |
| 2015-06-30 | $30.98 Million | +22.09% |
| 2014-06-30 | $25.38 Million | -22.66% |
| 2013-06-30 | $32.81 Million | -21.14% |
| 2012-06-30 | $41.61 Million | -27.81% |
| 2011-06-30 | $57.64 Million | +203.19% |
| 2010-06-30 | $19.01 Million | +663.62% |
| 2009-06-30 | $2.49 Million | -11.75% |
| 2008-06-30 | $2.82 Million | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more